|

Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin

RECRUITINGPhase 2Sponsored by Mahidol University
Actively Recruiting
PhasePhase 2
SponsorMahidol University
Started2026-02-10
Est. completion2027-10-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07699276

Summary

A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* histologically confirmed solid malignancy
* scheduled for first cycle of cisplatin at dosage of at least 50 mg/m2

Exclusion Criteria:

* pregnancy
* pelvic or abdominal radiation within 4 weeks
* uncontrolled brain metastasis
* other moderate or high emetic risk chemotherapy on day 2-5
* untreated gut obstruction
* known allergy or severe adverse effect from palonosetron or olanzapine
* AST/ ALT \> 2.5x or serum creatinine clearance less than 50 ml/min

Conditions5

CancerCancer (Solid Tumors)CisplatinOlanzapineVomiting

Interventions1

dexamethasone sparing

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.